Bio-Techne Corp
TECH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$29.00 | Dspjj | Rwgjkqpz |
Narrow-Moat Bio-Techne Reports Stellar End to 2020, Raising Fair Value Estimate to $215
Narrow-Moat Bio-Techne reported another very strong quarter, with year-over-year sales growth accelerating to over 20% and adjusted EPS increasing to $1.68 from $1.02 in the year-ago period. We are increasing our fair value estimate to $215 per share, up from $200, on the outperformance and management’s optimistic comments about the year ahead. We share the market’s positive view of earnings, with shares up over 10% in trading, in line with our fair value estimate increase. Still, shares remain significantly overvalued, in our view.